Topline Results From Pridopidine (Regimen D) of the Healey ALS Platform Trial

Today the topline results were announced from the pridopidine regimen of the HEALEY ALS Platform Trial.

The HEALEY ALS Platform Trial is designed to accelerate the development of breakthrough treatments for persons with ALS by testing multiple drugs at the same time. 

Please read the full announcement 

here

 

We extend our sincere gratitude to participants in the pridopidine regimen who committed their invaluable time and hope in the trial as well as the investigators and study staff who dedicated their effort and expertise.

We will be sharing additional details on a webinar on Monday, March 6th at 10 am EST. Register for the webinar 

here

.

All of our Best,

Your MGH Healey Center for ALS Team